Skip to main content
Umang Swami
( out of 138 reviews )

Umang Swami, MD, MSCI, FASCO

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
1950 Circle of Hope
Salt Lake City , UT 84112

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106

Umang Swami is an Associate Professor in the Division of Oncology, Department of Internal Medicine at Huntsman Cancer Institute, University of Utah. He is a specialist in medical oncology with a focus on genitourinary cancers. He completed his Medical School from Sawai Man Singh Medical College, India. Thereafter, he worked as a Visiting Scientist at Montefiore-Einstein Cancer Center, NY, and collaborated on phase I studies of novel drugs and regimens for patients with refractory or advanced solid tumors. He did his residency training in Internal Medicine at St. Barnabas Hospital, NY, Hematology-Oncology fellowship from the University of Iowa, and an MS in Clinical Investigations from the College of Public Health at the University of Iowa.


He has published over 150 peer-reviewed articles and book chapters and presented his research at various international conferences, including ASCO, AACR, and ASBMT. He is a reviewer and editor of multiple journals and a member of various professional societies like ASCO, AACR, ESMO, and SITC. He serves on the ASCO guideline panels for systemic melanoma therapy, immune-related adverse events management, and the Multi-Site Guideline Advisory Group. In addition, he is a current member of the Institutional Review Board (IRB), Radioactive Drug Research Committee (RDRC), and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC) at the University of Utah. He has mentored medical students, residents, and fellows interested in oncology research.

Specialties

Patient Rating

4.8 /5
( out of 138 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

Excellent everyone was very concerned and made us feel like they genuinely cared.

HUNTSMAN CANCER CENTER

very good experience.

HUNTSMAN CANCER CENTER

He is a great doctor, the treatment he picked for me 6 months ago, is working very good. He listened my concerns and understood my fears . He is smart and flexible trying to find a point of balance vetween my fears and my treatment and I think that is a beautiful skill in a doctor, for me, means he care about not just my body health but also my peace of mind. We are body, soul and mind, and in the treatment of cancer for me it was very important he listened and understood those 3 sides of myself.....I am very grateful to him and wish him a long and beautiful life helping people like me as he is doing.....

HUNTSMAN CANCER CENTER

He cares about his patients and answers questions patiently and with concern,

SUGAR HOUSE HEALTH CENTER

very thorough

SUGAR HOUSE HEALTH CENTER

good

HUNTSMAN CANCER CENTER

always very kind, caring, and professional would definitely recommend

HUNTSMAN CANCER CENTER

Only able to see his assistant

HUNTSMAN CANCER CENTER

Great!!!!!!!!

Umang Swami is an Associate Professor in the Division of Oncology, Department of Internal Medicine at Huntsman Cancer Institute, University of Utah. He is a specialist in medical oncology with a focus on genitourinary cancers. He completed his Medical School from Sawai Man Singh Medical College, India. Thereafter, he worked as a Visiting Scientist at Montefiore-Einstein Cancer Center, NY, and collaborated on phase I studies of novel drugs and regimens for patients with refractory or advanced solid tumors. He did his residency training in Internal Medicine at St. Barnabas Hospital, NY, Hematology-Oncology fellowship from the University of Iowa, and an MS in Clinical Investigations from the College of Public Health at the University of Iowa.


He has published over 150 peer-reviewed articles and book chapters and presented his research at various international conferences, including ASCO, AACR, and ASBMT. He is a reviewer and editor of multiple journals and a member of various professional societies like ASCO, AACR, ESMO, and SITC. He serves on the ASCO guideline panels for systemic melanoma therapy, immune-related adverse events management, and the Multi-Site Guideline Advisory Group. In addition, he is a current member of the Institutional Review Board (IRB), Radioactive Drug Research Committee (RDRC), and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC) at the University of Utah. He has mentored medical students, residents, and fellows interested in oncology research.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor
Academic Divisions Oncology

Selected Publications

Journal Article

  1. Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami (2025). Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations. JAMA network open, 8(10), e2534968.
  2. Nahle T, Makram OM, Shah VR, Hyma Kunhiraman H, Afzal MU, Riaz IB, Agarwal N, Swami U, Rachoin JS, Weintraub NL, Guha (2025). Socioeconomic position and its effect on cardiovascular outcomes and mortality in patients with prostate cancer. JNCI cancer spectrum, 9(6),
  3. Gebrael G, Agarwal N, Morgans AK, Vince R Jr, Swami U, Jia AY, Zaorsky N, Chehade CH, Ozay ZI, Malone S, Morgan SC, Wallis CJD, Kishan AU, Barata PC, Chowdhury S, Garcia JA, Sheng I, Brown JR, Small EJ, Sun Y, Shore ND, Saad F, Spratt DE, Roy (2026). Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. Cancer, 132(1), e70236.
  4. Roy S, Sun Y, Hussain M, Chi KN, Fizazi K, Davis ID, Halabi S, Agarwal N, Chowdhury S, Tombal B, Morgan SC, Malone S, Barata PC, Ong M, Wallis CJD, Berlin A, Swami U, Kishan AU, Jia AY, Zaorsky NG, Garcia JA, Mendiratta P, Brown JR, Subhash VV, Stockler MR, Thomas H, McKay RR, Small EJ, Shore ND, Saad F, Sweeney CJ, Spratt D (2025). Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer. Nature communications, 17(1), 667.
  5. Sayegh N, Graf RP, Swami U, Ozay ZI, Hage Chehade C, Elvin JA, Lin D, Quintanilha JCF, Li G, Bryce AH, McKay RR, Ross JS, Zhang T, Agarwal (2026). Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research, 32(4), 801-812.
  6. Swami U, Shao Q, Alfred T, Touya M, Cao F, Kamdar P, Ivanova J, Celli J, Nimke (2026). Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer. The Prostate,